Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Tonix Pharmaceuticals Holding Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Seth Lederman
İcra Kurulu Başkanı
US$2.1m
Toplam tazminat
CEO maaş yüzdesi | 32.9% |
CEO görev süresi | 13yrs |
CEO sahipliği | 0.0006% |
Yönetim ortalama görev süresi | 4.8yrs |
Yönetim Kurulu ortalama görev süresi | 6.1yrs |
Son yönetim güncellemeleri
Recent updates
CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$149m |
Mar 31 2024 | n/a | n/a | -US$99m |
Dec 31 2023 | US$2m | US$675k | -US$117m |
Sep 30 2023 | n/a | n/a | -US$123m |
Jun 30 2023 | n/a | n/a | -US$124m |
Mar 31 2023 | n/a | n/a | -US$123m |
Dec 31 2022 | US$5m | US$675k | -US$117m |
Sep 30 2022 | n/a | n/a | -US$112m |
Jun 30 2022 | n/a | n/a | -US$102m |
Mar 31 2022 | n/a | n/a | -US$98m |
Dec 31 2021 | US$8m | US$675k | -US$92m |
Sep 30 2021 | n/a | n/a | -US$80m |
Jun 30 2021 | n/a | n/a | -US$73m |
Mar 31 2021 | n/a | n/a | -US$64m |
Dec 31 2020 | US$4m | US$614k | -US$52m |
Sep 30 2020 | n/a | n/a | -US$46m |
Jun 30 2020 | n/a | n/a | -US$42m |
Mar 31 2020 | n/a | n/a | -US$34m |
Dec 31 2019 | US$1m | US$585k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$31m |
Jun 30 2019 | n/a | n/a | -US$28m |
Mar 31 2019 | n/a | n/a | -US$29m |
Dec 31 2018 | US$1m | US$473k | -US$29m |
Sep 30 2018 | n/a | n/a | -US$24m |
Jun 30 2018 | n/a | n/a | -US$24m |
Mar 31 2018 | n/a | n/a | -US$23m |
Dec 31 2017 | US$576k | US$473k | -US$21m |
Tazminat ve Piyasa: Seth's total compensation ($USD2.05M) is above average for companies of similar size in the US market ($USD667.78K).
Tazminat ve Kazançlar: Seth's compensation has been consistent with company performance over the past year.
CEO
Seth Lederman (66 yo)
13yrs
Görev süresi
US$2,050,065
Tazminat
Dr. Seth Lederman, M. D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 13yrs | US$2.05m | 0.00065% $ 21.2 | |
CFO & Treasurer | 8.7yrs | US$904.91k | 0.000020% $ 0.7 | |
Chief Operating Officer | 8.7yrs | US$928.60k | 0% $ 0 | |
Chief Medical Officer & Secretary | 7.6yrs | US$952.00k | 0.000070% $ 2.3 | |
Executive Vice President of Translational Medicine | 4.4yrs | Veri yok | Veri yok | |
Executive Vice President of Product Development | no data | Veri yok | Veri yok | |
Executive Vice President of Experimental Chemistry | 4.8yrs | Veri yok | Veri yok | |
Executive Vice President of Infectious Disease Research & Development | 2.3yrs | Veri yok | Veri yok | |
Executive Vice President of Medical | 1.8yrs | Veri yok | Veri yok | |
Executive Vice President of Commercial Operations | less than a year | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: TNXP's management team is considered experienced (4.8 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 13yrs | US$2.05m | 0.00065% $ 21.2 | |
Independent Director | 6.1yrs | US$82.48k | 0% $ 0 | |
Independent Director | 1.6yrs | US$113.05k | 0% $ 0 | |
Independent Director | 6.7yrs | US$82.48k | 0% $ 0 | |
Independent Director | 7.1yrs | US$82.48k | 0% $ 0 | |
Independent Director | 4.3yrs | US$82.48k | 0.000010% $ 0.3 | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Independent Lead Director | 5.7yrs | US$102.48k | 0.000010% $ 0.3 | |
Member of Scientific Advisory Board | 13.3yrs | Veri yok | Veri yok | |
Independent Director | 3.3yrs | US$82.48k | 0% $ 0 |
6.1yrs
Ortalama Görev Süresi
66.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: TNXP's board of directors are considered experienced (6.1 years average tenure).